(NASDAQ: ENGN) Engene Holdings's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.92%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 35.94%.
Engene Holdings's earnings in 2026 is -$122,438,000.On average, 13 Wall Street analysts forecast ENGN's earnings for 2026 to be -$168,893,842, with the lowest ENGN earnings forecast at -$204,170,494, and the highest ENGN earnings forecast at -$138,567,710. On average, 13 Wall Street analysts forecast ENGN's earnings for 2027 to be -$146,994,985, with the lowest ENGN earnings forecast at -$193,010,049, and the highest ENGN earnings forecast at -$77,372,833.
In 2028, ENGN is forecast to generate -$100,444,005 in earnings, with the lowest earnings forecast at -$194,979,540 and the highest earnings forecast at $4,923,726.